Panel Discussion: Positioning Microbiome Science & Clinical Translation to Meet Mainstream VC Investment Criteria Early
- Defining core investment checklists used by generalist biotech VCs to assess microbiome opportunities, enabling alignment of narratives with decision drivers
- Diagnosing causes of investor skepticism following early company failures to reposition data packages, risk profiles, and timelines for renewed confidence
- Attracting non-specialist venture investors by translating complex biology into clear value propositions and commercial milestones to expand the capital pool